Cardiovascular

FDA approves Ferriprox for thalassemia patients with iron overload from blood transfusions

The U.S. Food and Drug Administration has Ferriprox (deferiprone) for the treatment of iron overload caused by blood transfusions in patients with thalassemia. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares